艾塞那肽皮下输注与2型糖尿病心血管结局:一项非劣效随机对照试验
在伴有或存在动脉粥样硬化性心血管疾病风险的2型糖尿病患者中,随机分配接受艾塞那肽持续皮下输注(ITCA 650)或安慰剂,主要复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中或不稳定型心绞痛住院)发生率在ITCA 650组为4.6%,安慰剂组为3.8%,达到预设非劣效标准(HR=1.21,95%CI 0.90-1.63,P非劣效=0.004)。ITCA 650组不良事件更频繁,主要因胃肠道事件增加。
要点
- ITCA 650组主要复合终点发生率为4.6%(95/2,075),安慰剂组为3.8%(79/2,081),达到非劣效标准(HR=1.21,95%CI 0.90-1.63)。
- ITCA 650组不良事件发生率为72%(1,491/2,074),高于安慰剂组的63.9%(1,325/2,070),主要因胃肠道事件增加。
- 两组严重不良事件相似;作者认为需要更大规模、更长疗程的心血管结局试验来更精确地定义ITCA 650的心血管效应。
核心结论
- 在伴有或存在动脉粥样硬化性心血管疾病风险的2型糖尿病患者中,ITCA 650在主要复合心血管终点上非劣于安慰剂。
研究设计与样本
- 随机对照非劣效性试验(NCT01455896),纳入4,156例伴有或存在动脉粥样硬化性心血管疾病风险的2型糖尿病患者,随机分为ITCA 650组(2,075例)和安慰剂组(2,081例),中位随访16个月。
主要发现
- 主要复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中或不稳定型心绞痛住院)在ITCA 650组发生率为4.6%(95/2,075),安慰剂组为3.8%(79/2,081)。
- 风险比HR=1.21(95%CI 0.90-1.63),P非劣效=0.004,达到预设非劣效标准(基于2008年美国食品药品监督管理局指南,HR的95%CI上限非劣效界值为1.8)。
- 严重不良事件两组相似;不良事件ITCA 650组为72%(1,491/2,074),安慰剂组为63.9%(1,325/2,070),主要因ITCA 650治疗期间胃肠道事件和疾病增加。
关键数值与推荐
- 非劣效界值:HR的95%CI上限为1.8(基于2008年美国食品药品监督管理局指南)。
- 主要终点非劣效检验结果:HR=1.21,95%CI 0.90-1.63,P非劣效=0.004。
临床怎么用
- 作者认为需要更大规模、更长疗程的心血管结局试验来更精确地定义ITCA 650在该人群中的心血管效应。
局限性
- 作者指出需要更大规模、更长疗程的心血管结局试验来更精确地定义ITCA 650在该人群中的心血管效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) injected periodically have been shown to not increase and, for some members of this class, decrease the risk of cardiovascular events. The cardiovascular safety of delivering a continuous subcutaneous infusion of the GLP-1RA exenatide (ITCA 650) is unknown. Here, we randomly assigned patients with type 2 diabetes with, or at risk for, atherosclerotic cardiovascular disease (ASCVD) to receive ITCA 650 or placebo to assess cardiovascular safety in a pre-approval trial ( NCT01455896 ). The primary outcome was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or hospitalization for unstable angina. On the basis of 2008 guidance from the US Food and Drug Administration, a non-inferiority margin of 1.8 for the upper bound of the 95% confidence interval (CI) of the hazard ratio (HR) was used. We randomized 4,156 patients (2,075 assigned to receive ITCA 650 and 2,081 assigned to receive placebo) who were followed for a median of 16 months. The primary outcome occurred in 4.6% (95/2,075) of patients in the ITCA 650 group and 3.8% (79/2,081) of patients in the placebo group, meeting the pre-specified non-inferiority criterion (HR = 1.21, 95% CI, 0.90-1.63, Pnon-inferiority = 0.004). Serious adverse events were similar between the two groups. Adverse events were more frequent in the ITCA 650 group (72%, 1,491/2,074) than in the placebo group (63.9%, 1,325/2,070), mainly due to an increase in gastrointestinal events and disorders while on ITCA 650. In patients with type 2 diabetes with, or at risk for, ASCVD, ITCA 650 was non-inferior to placebo. A larger and longer-duration cardiovascular outcomes trial is needed to define more precisely the cardiovascular effects of ITCA 650 in this population.
引用
- Ruff CT, Baron M, Im K, et al. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med. 2021. PMID: 34873344. doi:10.1038/s41591-021-01584-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。